Communicating Uncertainties Associated With the Benefits and Risks of New Cancer Drugs

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
London School of Economics and Political Science
Study ID
NCT06997185
Status
Recruiting
Apply to this trial

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Statement communicating uncertainty with a single arm trial — OTHER
    Because Zenova has not been compared to other treatments, it is unknown if Zenova is better, the same, or worse than other treatments for non-small cell lung cancer.
  • Statement communicating uncertainty with limited study duration — OTHER
    Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
  • Statement communicating uncertainty with a limited study population — OTHER
    Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
  • Statement communicating uncertainty with an unvalidated surrogate endpoint — OTHER
    Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
  • Statement communicating uncertainty with treatment effect size — OTHER
    It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.

Study Details

This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate different sources of uncertainty about the benefits and harms of new cancer drugs on participants' decisions and understanding.

Key Dates

Start date
May 9, 2025
Status verified
May 2025
Primary completion
Jun 30, 2025
Completion
Jun 30, 2025

Study Design

Enrollment
3,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Experimental: Single arm trial
  • Experimental: Limited study duration (long-term benefits and harms)
  • Experimental: Limited study population (generalizability)
  • Experimental: Unvalidated surrogate endpoint
  • Experimental: Treatment effect size (magnitude of benefit)

Primary Outcome Measure

Change in decisions [ Time Frame: 15-minute survey. Change in decisions is assessed by participants answers to the question pre- and post-intervention. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Harvard Medical School and Harvard Pilgrim Health Care InstituteBostonMassachusetts02139
Avi Cherla
[email protected]
617-201-1718
Avi Cherla (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Harvard Medical School and Harvard Pilgrim Health Care Institute· Boston, MA

Related Studies